Fishman J, Anderson S, Talbird SE, Dingli D. Analysis of costs per responder in US adults with a paroxysmal nocturnal hemoglobinuria with suboptimal response to prior eculizumab treatment. Hematol Rep. 2023 Oct 13;15(4):578-91. doi: 10.3390/hematolrep15040060
Gascon M, Cirach M, Martinez D, Dadvand P, Valentin A, Plasencia A, Nieuwenhuijsen MJ. Normalized difference vegetation index (NDVI) as a marker of surrounding greenness in epidemiological studies: the case of Barcelona city. Urban For Urban Green. 2016 Sep;19:88-94. doi: 10.1016/j.ufug.2016.07.001
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
McKenna SP, Whalley D, Doward LC. Which outcomes are important in schizophrenia? Int J Methods Psychiatr Res. 2000;9(1):S58-67.